Literature DB >> 10977388

Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application.

M Sculpher1, E Fenwick, K Claxton.   

Abstract

Despite the growing use of decision analytic modelling in cost-effectiveness analysis, there is a relatively small literature on what constitutes good practice in decision analysis. The aim of this paper is to consider the concept of 'validity' and 'quality' in this area of evaluation, and to suggest a framework by which quality can be demonstrated on the part of the analyst and assessed by the reviewer and user. The paper begins by considering the purpose of cost-effectiveness models and argues that the their role is to identify optimum treatment decisions in the context of uncertainty about future states of the world. The issue of whether such models can be defined as 'scientific' is considered. The notion that decision analysis undertaken at time t can only be considered scientific if its outputs closely predict the results of a trial undertaken at time t + 1 is rejected as this ignores the need to make decisions on the basis of currently available evidence. Rather, the scientific characteristic of decision models is based on the fact that, in principle at least, such analyses can be falsified by comparison of two states of the world, one where resource allocation decisions are based on formal decision analysis and the other where such decisions are not. This section of the paper also rejects the idea of exact codification of scientific method in general, and of decision analysis in particular, as this risks rejecting potentially valuable models, may discourage the development of novel methods and can distort research priorities. However, the paper argues that it is both possible and necessary to develop a framework for assessing quality in decision models. Building on earlier work, various dimensions of quality in decision modelling are considered: model structure (disease states, options, time horizon and cycle length); data (identification, incorporation, handling uncertainty); and consistency (internal and external). Within this taxonomy a (nonexhaustive) list of questions about quality is suggested which are illustrated by their application to a specific published model. The paper argues that such a framework can never be prescriptive about every aspect of decision modelling. Rather, it should encourage the analyst to provide an explicit and comprehensive justification of their methods, and allow the user of the model to make an informed judgment about the relevance, coherence and usefulness of the analysis.

Mesh:

Year:  2000        PMID: 10977388     DOI: 10.2165/00019053-200017050-00005

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  30 in total

1.  Applications of modelling studies.

Authors:  M J Nuijten; J Starzewski
Journal:  Pharmacoeconomics       Date:  1998-03       Impact factor: 4.981

2.  Monte Carlo techniques for quantitative uncertainty analysis in public health risk assessments.

Authors:  K M Thompson; D E Burmaster; E A Crouch
Journal:  Risk Anal       Date:  1992-03       Impact factor: 4.000

3.  Problems of using modelling in the economic evaluation of health care.

Authors:  T A Sheldon
Journal:  Health Econ       Date:  1996 Jan-Feb       Impact factor: 3.046

4.  Letter: Grading of angina pectoris.

Authors:  L Campeau
Journal:  Circulation       Date:  1976-09       Impact factor: 29.690

5.  Modelling in economic evaluation: an unavoidable fact of life.

Authors:  M J Buxton; M F Drummond; B A Van Hout; R L Prince; T A Sheldon; T Szucs; M Vray
Journal:  Health Econ       Date:  1997 May-Jun       Impact factor: 3.046

6.  Assessing the responsiveness of functional scales to clinical change: an analogy to diagnostic test performance.

Authors:  R A Deyo; R M Centor
Journal:  J Chronic Dis       Date:  1986

7.  Determining transition probabilities: confusion and suggestions.

Authors:  D K Miller; S M Homan
Journal:  Med Decis Making       Date:  1994 Jan-Mar       Impact factor: 2.583

8.  Toward a peer review process for medical decision analysis models.

Authors:  F A Sonnenberg; M S Roberts; J Tsevat; J B Wong; M Barry; D L Kent
Journal:  Med Care       Date:  1994-07       Impact factor: 2.983

Review 9.  'Evidence-based', 'cost-effective' and 'preference-driven' medicine: decision analysis based medical decision making is the pre-requisite.

Authors:  J Dowie
Journal:  J Health Serv Res Policy       Date:  1996-04

10.  Empirically defined health states for depression from the SF-12.

Authors:  C A Sugar; R Sturm; T T Lee; C D Sherbourne; R A Olshen; K B Wells; L A Lenert
Journal:  Health Serv Res       Date:  1998-10       Impact factor: 3.402

View more
  61 in total

1.  Using economic evaluations to reduce the burden of asthma and chronic obstructive pulmonary disease.

Authors:  M Sculpher
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  A guideline for the use of pharmacoeconomic models of diabetes treatment in the US managed-care environment.

Authors:  David L Veenstra; Scott D Ramsey; Sean D Sullivan
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

3.  A proposed model for economic evaluations of major depressive disorder.

Authors:  Hossein Haji Ali Afzali; Jonathan Karnon; Jodi Gray
Journal:  Eur J Health Econ       Date:  2011-06-02

4.  Population- versus cohort-based modelling approaches.

Authors:  Olivier Ethgen; Baudouin Standaert
Journal:  Pharmacoeconomics       Date:  2012-03       Impact factor: 4.981

5.  Incorporation of uncertainty in health economic modelling studies.

Authors:  Anthony O'Hagan; Christopher McCabe; Ron Akehurst; Alan Brennan; Andrew Briggs; Karl Claxton; Elisabeth Fenwick; Dennis Fryback; Mark Sculpher; David Spiegelhalter; Andrew Willan
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 6.  Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature.

Authors:  Rachael L Fleurence; Cynthia P Iglesias; David J Torgerson
Journal:  Osteoporos Int       Date:  2005-06-25       Impact factor: 4.507

Review 7.  Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment.

Authors:  Zoë Philips; Laura Bojke; Mark Sculpher; Karl Claxton; Su Golder
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 8.  A review of health care models for coronary heart disease interventions.

Authors:  K Cooper; S C Brailsford; R Davies; J Raftery
Journal:  Health Care Manag Sci       Date:  2006-11

9.  Rates and probabilities in economic modelling: transformation, translation and appropriate application.

Authors:  Rachael L Fleurence; Christopher S Hollenbeak
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

10.  Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications.

Authors:  Javier Soto
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.